NCT02203643 2026-04-14
FORTE
University of Turin, Italy
Phase 2 Completed
Clinical Trials
15 trialsNCT03500445 2026-04-13
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT06948084 2026-04-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT02405364 2026-04-08
IFM-CRd
University Hospital, Toulouse
Phase 2 Completed
NCT02302495 2026-04-07
IFM2012-03
University Hospital, Lille
Phase 2 Completed
NCT01813227 2026-04-03
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Phase 2 Completed
NCT04933539 2026-04-01
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
NCT01572480 2026-03-10
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04661137 2026-02-10
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Suspended
NCT04113018 2026-02-03
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05497804 2026-02-03
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting